FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L. Suzman, Julia A. Beaver, Laura L. Fernandes et al.|The Oncologist|2018Cited by 200
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn Howie, Julia A. Beaver, Nancy S. Scher et al.|Clinical Cancer Research|2018Cited by 68